Montelukast Glenmark Pharmaceuticals Europe (Montelukast Sodium)

Montelukast, the active ingredient in Montelukast Glenmark Pharmaceuticals Europe, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It treats asthma, exercise‑induced bronchoconstriction and allergic rhinitis in adults and children.

GNH USA supplies Montelukast Glenmark Pharmaceuticals Europe as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast is indicated for conditions involving leukotriene‑mediated airway inflammation.

- Asthma: improves long‑term control of symptoms and reduces exacerbations in patients requiring maintenance therapy. - Exercise‑induced bronchoconstriction: prevents narrowing of airways triggered by physical activity. - Allergic rhinitis: alleviates nasal congestion, sneezing and itchy eyes associated with seasonal or perennial allergic rhinitis.

Montelukast may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache - Abdominal pain - Cough - Sore throat - Nausea - Dizziness

Serious or Rare Side Effects: - Allergic reactions such as angioedema or anaphylaxis - Mood changes including depression or suicidal thoughts - Elevated liver enzymes or hepatitis - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Eosinophilic granulomatosis with polyangiitis (rare)

Before initiating therapy, consider the following precautions.

- Pregnancy: safety not established; use only if potential benefit justifies the risk. - Breastfeeding: unknown safety; weigh maternal benefit against potential infant exposure. - Concomitant strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce drug exposure. - Renal or hepatic impairment: monitor clinical response and adjust if necessary. - Known hypersensitivity to montelukast or any excipients: avoid use. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture.

Montelukast can interact with several medicines; assess the clinical relevance before co‑administration.

Major Interactions (Avoid): - Phenobarbital, rifampin, carbamazepine: may markedly lower montelukast plasma concentrations. - Strong CYP3A4 inducers: may diminish therapeutic effect.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR; monitor coagulation parameters. - Theophylline: additive central nervous system effects may occur. - Fluconazole: may raise montelukast levels; observe for enhanced adverse reactions.